<DOC>
	<DOC>NCT00284271</DOC>
	<brief_summary>This study is designed to test (1) feasibility and efficiancy of new BACOPP regimen and (2) toxicity, overall response and FFTF.</brief_summary>
	<brief_title>Feasibility and Efficacy of BACOPP-21 for Patients &gt; 60 Years With Intermediate or Advanced Hodgkins Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Hodgkin´s lymphoma (histologically proven) CS (PS) I and II with one of the risk factors ad 1. bulky mediastinal mass (&gt; 1/3 maximum transverse thorax diameter) 2. extranodal involvement 3. ESR &gt; 50 (A), &gt; 30 (Bsymptoms) 4. 3 or more lymph node areas involved CS (PS) III and IV Written informed consent Leukocytes &lt;3000/microl Platelets &lt;100000/microl Hodgkin´s Disease as "composite lymphoma" Activity index (WHO) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin´s Lymphoma</keyword>
	<keyword>eldery patients</keyword>
	<keyword>primary diagnosis</keyword>
</DOC>